The Pennant Group, Inc. (PNTG)
| Market Cap | 1.25B +42.4% |
| Revenue (ttm) | 1.02B +36.8% |
| Net Income | 30.32M +19.2% |
| EPS | 0.86 +13.0% |
| Shares Out | 34.77M |
| PE Ratio | 41.73 |
| Forward PE | 25.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 384,603 |
| Open | 35.64 |
| Previous Close | 35.73 |
| Day's Range | 35.31 - 37.54 |
| 52-Week Range | 21.73 - 37.54 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+8.64%) |
| Earnings Date | May 6, 2026 |
About PNTG
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides seni... [Read more]
Financial Performance
In 2025, The Pennant Group's revenue was $947.71 million, an increase of 36.31% compared to the previous year's $695.24 million. Earnings were $29.58 million, an increase of 31.11%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PNTG stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 8.64% from the latest price.
News
Pennant Group price target raised to $40 from $37 at Oppenheimer
Oppenheimer raised the firm’s price target on Pennant Group (PNTG) to $40 from $37 and keeps an Outperform rating on the shares following the company’s earnings reported. The firm argues
Pennant Group price target raised to $42 from $36 at Truist
Truist raised the firm’s price target on Pennant Group (PNTG) to $42 from $36 and keeps a Buy rating on the shares. The firm remains bullish on Pennant post-strong Q1
The Pennant Group Earnings Call Transcript: Q1 2026
Q1 2026 saw 36% revenue growth and strong margin expansion, driven by robust Home Health, Hospice, and Senior Living performance. Integration of Southeast acquisitions is on track, with guidance pointed to the upper end of the range and continued operational improvements expected.
Pennant Reports First Quarter 2026 Results
EAGLE, Idaho, May 06, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today ann...
Pennant Announces First Quarter 2026 Earnings Release and Call
EAGLE, Idaho, May 04, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announ...
Pennant Group acquires three senior living communities in Arizona, Wisconsin
The Pennant Group (PNTG) announced that effective May 1, it has assumed operations of three senior living communities across Arizona and Wisconsin, expanding Pennant’s operations by 194 units. The thr...
Pennant Acquires Senior Living Communities in Arizona and Wisconsin
EAGLE, Idaho, May 01, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies...
Pennant Group price target raised to $36 from $34 at Truist
Truist analyst David MacDonald raised the firm’s price target on Pennant Group (PNTG) to $36 from $34 and keeps a Buy rating on the shares as part of a broader
Pennant Group acquires real estate, operations of Arbor Rose Senior Living
Pennant Group (PNTG) announced the acquisition of the real estate and operations of Arbor Rose Senior Living, a senior living community located in Mesa, Arizona, which will now be known
Pennant Acquires Arbor Rose Senior Living Community in Mesa, Arizona
EAGLE, Idaho, April 01, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living compani...
The Pennant Group Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Momentum continues following major acquisitions, with integration progressing in five waves through October. Margin expansion is targeted across segments, and a strong leadership pipeline supports both organic and acquisitional growth. Investments in technology and a flexible, local leadership model are expected to drive future value.
UPDATE – Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
EAGLE, Idaho, March 17, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announc...
Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
EAGLE, Idaho, March 16, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announc...
Pennant Group price target raised to $41 from $39 at RBC Capital
RBC Capital raised the firm’s price target on Pennant Group (PNTG) to $41 from $39 and keeps an Outperform rating on the shares. The company’s 2026 adjusted EBITDA guidance came
The Pennant Group Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 36% revenue growth and exceeded EPS guidance. 2026 outlook projects continued double-digit growth, driven by recent acquisitions, operational improvements, and robust segment performance, with a focus on integration and margin expansion.
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
EAGLE, Idaho, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today an...
Pennant Announces Fourth Quarter and Year-End 2025 Earnings Release and Call
EAGLE, Idaho, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, annou...
Pennant Group price target raised to $38 from $31 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Pennant Group (PNTG) to $38 from $31 and keeps an Overweight rating on the shares. For managed care organizations,
Pennant Group price target raised to $40 from $30 at Jefferies
Jefferies raised the firm’s price target on Pennant Group (PNTG) to $40 from $30 and keeps a Buy rating on the shares. The firm raised its price target to reflect
Pennant Group initiated with an Outperform at William Blair
William Blair initiated coverage of Pennant Group (PNTG) with an Outperform rating. The firm views Pennant as an attractive small-cap growth investment and notes that shares trade at a multiple
Pennant Group upgraded to Buy from Hold at Truist
Truist analyst David MacDonald upgraded Pennant Group (PNTG) to Buy from Hold with a price target of $34, up from $28. The upgrade reflects confidence in the company’s complementary business
Pennant Group upgraded to Buy from Hold at Truist
Truist upgraded Pennant Group (PNTG) to Buy from Hold with a $34 price target
The Pennant Group Transcript: Stephens Annual Investment Conference
Major acquisitions and organic growth drove strong 2025 results, with disciplined integration and leadership development at the core. Partnerships and JVs expanded market reach, while operational improvements in Home Health, Hospice, and Senior Living segments supported margin and occupancy gains.
Wells upgrades Pennant Group on potential reimbursement upside
Wells Fargo analyst Stephen Baxter upgraded Pennant Group (PNTG) to Overweight from Equal Weight with a price target of $31, up from $29. The firm sees upside in the stock
Pennant Group upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Stephen Baxter upgraded Pennant Group (PNTG) to Overweight from Equal Weight with a price target of $31, up from $29.